Recruiting studies: Breast Cancer Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043 The PREDICT Registry:
Phase N/A · 30 location(s) · PreludeDx · NCT03448926 YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07461454 Opioid-free Anaesthesia in Breast Cancer Surgery
NA · 1 location(s) · University of Ioannina · NCT06404983 Psychoeducation and Well-Being After Breast Cancer
NA · 1 location(s) · Yasemin Nazli · NCT07284030 Thermotherapy in Addition to SOC Palliative Radiotherapy
NA · 2 location(s) · King's College London · NCT06659146 Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Phase 2 · 7 location(s) · Dana-Farber Cancer Institute · NCT04434040 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic
Phase 3 · 72 location(s) · National Cancer Institute (NCI) · NCT07391774 A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1 · 6 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06908928 Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography
NA · 1 location(s) · Royal College of Surgeons, Ireland · NCT07443579 A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760 Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT04899908 Triple Negative Breast Cancer and Celecoxib. Pilot Study
Phase 2 · 1 location(s) · Université de Sherbrooke · NCT07104266 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Phase 3 · 42 location(s) · West German Study Group · NCT06081244 Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recur
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05838066 CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Phase N/A · 1 location(s) · RenJi Hospital · NCT05795335 Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT06900647 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961 Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
Phase N/A · 1 location(s) · Center Eugene Marquis · NCT06358625 Breast Cancer Proteomics and Molecular Heterogeneity
Phase N/A · 6 location(s) · Cancer Trials Ireland · NCT01840293 Partial Breast Versus no Irradiation for Women With Early Breast Cancer
NA · 17 location(s) · Danish Breast Cancer Cooperative Group · NCT03646955 Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976 A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent
Phase 3 · 25 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07003074 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 102 location(s) · DualityBio Inc. · NCT05150691 A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · 53 location(s) · Puma Biotechnology, Inc. · NCT06369285 KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
Phase 2 · 10 location(s) · Institute of Cancer Research, United Kingdom · NCT03946202 Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Phase 2 · 1 location(s) · University of Utah · NCT05464082 Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
Phase 3 · 1 location(s) · Japanese Foundation for Cancer Research · NCT07190443 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.